Skip to main content

Perlegen and Genentech to Study Genetics of Cancer

NEW YORK, Dec. 6 (GenomeWeb News) - Perlegen Sciences announced today that it has begun a collaboration with Genentech to study the genetics of cancer.

 

The companies hope to apply findings to the discovery and development of targeted medicines and molecular diagnostics for cancer.

 

Perlegen uses Affymetrix's GeneChip technology in its high-throughput oligonucleotide array approach.

 

Terms of the agreement were not disclosed.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.